ArticleJournal of orthopaedic surgery and research2025
GLP-2-carrying exosomes alleviate osteoporosis by upregulating miR-378a-3p to inhibit osteoclastic differentiation and NF-κB-MAPK pathway.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation.International journal of nanomedicine · 2026Review
- Application of circadian rhythm in osteoporosis prevention and treatment: from light, diet, and exercise to chronotherapy.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis, characterized by excessive osteoclast activity, remains a major health challenge. This study investigated the therapeutic potential of exosomes derived from glucagon-like peptide-2 (GLP-2)-overexpressing macrophages in osteoporosis, with specific focus on miR-378a-3p-mediated regulation of osteoclastogenesis and inflammatory signaling pathways.
methodsGLP-2 was overexpressed in mouse RAW264.7 cells. Exosomes were extracted and characterized. In vitro, effects on osteoclast differentiation were assessed using Cell Counting Kit-8, tartrate-resistant acid phosphatase staining, and quantitative real-time polymerase chain reaction. Differentially expressed miRNAs were screened via bioinformatics analysis. In vivo, an osteoporosis rat model was induced by bilateral ovariectomy. Histopathological evaluation of femoral tissue was performed via Hematoxylin-Eosin and tartrate resistant acid phosphatase staining. Bone microarchitecture, inflammatory cytokines, and signaling pathways were evaluated using micro-CT, enzyme-linked immunosorbent assay, and western blotting. Moreover, miR-378a-3p antagonist was applied to investigate the role of miR-378a-3p in osteoporosis.
resultsGLP-2-carrying exosomes inhibited osteoclast differentiation in vitro and improved bone microarchitecture in vivo. Bioinformatics analysis identified miR-378a-3p as a hub miRNA and miR-378a-3p was downregulated in osteoporosis. In vivo, GLP-2-carrying exosomes promoted miR-378a-3p level and inhibited osteoclast differentiation. MiR-378a-3p mimics inhibited the NF-κB/MAPK signaling, and the direct binding specificity between miR-378a-3p and TRAF6 was validated via dual-luciferase reporter assay. Mechanistically, GLP-2-carrying exosomes enhanced bone parameters, suppressed inflammation and NF-κB/MAPK signaling pathway, which were reversed by miR-378a-3p antagonist.
conclusionGLP-2-carrying exosomes showed promise in treating osteoporosis by inhibiting osteoclast differentiation and modulating NF-κB/MAPK pathways via miR-378a-3p regulation. This novel axis presents a promising dual-targeted strategy for osteoporosis treatment, with engineered exosomes offering significant translational potential for bone regenerative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.